HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization
- 30 July 1997
- journal article
- Published by Elsevier in Human Pathology
- Vol. 28 (7) , 827-833
- https://doi.org/10.1016/s0046-8177(97)90157-x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapyCancer, 1994
- Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast CancerAnnals of Surgery, 1994
- Changes in prostate cancer incidence and treatment in USAThe Lancet, 1994
- Results of Conservative Management of Clinically Localized Prostate CancerNew England Journal of Medicine, 1994
- Contribution of HER‐2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasisCancer, 1993
- Expression of the c-erbB-2 (Her-2/neu) Oncoprotein in Human Prostatic CarcinomaJournal of Urology, 1993
- Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.Journal of Clinical Oncology, 1993
- Overexpression of Her-2/Neu may be an Indicator of Poor Prognosis in Prostate CancerJournal of Urology, 1993
- Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissuesSurgical Oncology, 1992